Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma: Frontiers in Immunology

F. Sabbatino, G. Scognamiglio, L. Liguori, A. Marra, A.M. Anniciello, G. Polcaro, J. Dal Col, A. Caputo, A.L. Peluso, G. Botti, P. Zeppa, S. Ferrone, S. Pepe

Research output: Contribution to journalArticlepeer-review


Thin melanomas are tumors less than 1 mm thick according to Breslow classification. Their prognosis is in most cases excellent. However, a small subset of these tumors relapses. These clinical findings emphasize the need of novel prognostic biomarkers to identify this subset of tumors. Characterization of tumor immune microenvironment (TIME) is currently investigated as a prognostic and predictive biomarker for cancer immunotherapy in several solid tumors including melanoma. Here, taking into account the limited availability of tumor tissues, by characterizing some of the characteristics of TIME such as number of infiltrating lymphocytes, HLA class I antigen and PD-L1 expression, we show that number of infiltrating CD8+ and FOXP3+ T cells as well as CD8+/FOXP3+ T cell ratio can represent a useful prognostic biomarker in thin melanoma. Although further investigations in a larger patient cohort are needed, these findings have potential clinical significance since they can be used to define subgroups of thin melanoma patients who have a worse prognosis and might need different treatment modalities. © Copyright © 2020 Sabbatino, Scognamiglio, Liguori, Marra, Anniciello, Polcaro, Dal Col, Caputo, Peluso, Botti, Zeppa, Ferrone and Pepe.
Original languageEnglish
JournalFront. Immunol.
Publication statusPublished - 2020


  • CD4
  • CD8
  • human leukocyte antigen class I antigens
  • prognosis
  • programmed death-ligand 1
  • thin melanoma
  • time
  • tumor-infiltrating lymphocytes


Dive into the research topics of 'Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma: Frontiers in Immunology'. Together they form a unique fingerprint.

Cite this